Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

NCT00616551 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Acromegaly

Interventions

DRUG: C2L-OCT-01 PR, 30 mg
DRUG: Octreotide acetate prolonged release, 30 mg

Sponsor

Ambrilia Biopharma, Inc.